An Open-label Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Xentuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 13 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
- 24 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.